Mercado global de tratamento da vasculite Anca – Tendências do setor e previsão para 2028

Análise de mercado e insights: Mercado global de tratamento da vasculite Anca

Espera-se que o mercado de tratamento da vasculite anca ganhe crescimento de mercado no período de previsão de 2021 a 2028. A Data Bridge Market Research analisa que o mercado está a crescer a um CAGR de 5,90% no período de previsão de pesquisa acima mencionado. O aumento dos desenvolvimentos recentes e a aprovação da terapêutica medicamentosa pela FDA podem impulsionar o crescimento do mercado de tratamento da vasculite anca.

Por exemplo,

• O medicamento Avacopan da ChemoCentryx, Inc. foi aceite como um novo pedido de medicamento pela FDA para o tratamento da vasculite anca. O medicamento é administrado por via oral e é formulado de forma a bloquear o recetor do complemento 5a (C5aR) nas células inflamatórias destrutivas conhecidas como neutrófilos. O NDA inclui o ensaio clínico de fase III do medicamento. O relatório sugeriu que o medicamento foi eficaz com poucos efeitos secundários.

A vasculite é definida como inflamação ou inchaço nos vasos sanguíneos. A vasculite ANCA é um tipo de doença autoimune responsável pela vasculite. O ANCA significa Autoanticorpo citoplasmático anti-neutrofílico. Afeta principalmente os pequenos vasos sanguíneos e o ANCA ataca os leucócitos denominados neutrófilos. Estes neutrófilos atacam então os vasos sanguíneos, fazendo com que os vasos sanguíneos fiquem inchados e inflamados. Os sintomas desta doença dependem do órgão que está infectado, como se o ANCA atacar os vasos sanguíneos, ocorrer erupção cutânea à medida que os sintomas ocorrem e se atacar os rins , pode causar danos nos rins e muitos mais sintomas. Ocorre sobretudo na população com idades compreendidas entre os 50 e os 60 anos e é frequente em homens e mulheres.  

The rising prevalence of inflammatory disease of blood vessels and increase in geriatric population are other factors for the anca vasculitis treatment market growth. For instance, the prevalence for anca vasculitis is 4.6-18.4 cases per 100,000 worldwide whereas the incidence for the same disease is 1.2 to 2.0 cases per 100,000 people. Complications of the therapies for the ANCA vasculitis treatment such as organ damage, cardiovascular diseases and disabilities. Long term immunosuppressive therapy can affect the fertility rate and bones health which are some of the restraining factor for the anca vasculitis treatment market growth.

Challenging factor for the anca vasculitis treatment market growth is the diagnosis of vasculitis of those patients who are dependent on the dialysis that is dialysis dependent kidney disease because prescribing them toxic immunosuppressive therapy or initiation therapy can be a difficult task for the physician because the patient does not show any response of the treatment.   

This anca vasculitis treatment market provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions and technological innovations in the market. To understand the analysis and the anca vasculitis treatment market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Anca Vasculitis Treatment Market Scope and Market Size

The anca vasculitis treatment market is segmented on the basis of type, diagnosis, treatment type, route of administration, end user and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

• On the basis of type, the anca vasculitis treatment market is segmented into microscopic polyangiitis, granulomatosis with polyangiitis and eosinophilic granulomatosis with polyangiitis.
• On the basis of diagnosis, the anca vasculitis treatment market is segmented into blood test, urine test, X-ray, CT scan, bronchoscopy and biopsy.
• On the basis of treatment type, the anca vasculitis treatment market is segmented into induction therapy, maintenance therapy and other. Induction therapy is further segmented to rituximab (rituxan), cyclophosphamide (cytoxan) and plasmapheresis. Maintenance therapy is further segmented to azathioprine (imuran). Other is further segmented to mycophenolate mofetil (cellCept or myfortic).
• On the basis of route of administration, the anca vasculitis treatment market is segmented into oral and parenteral.
• On the basis of end user, the anca vasculitis treatment market is segmented into government hospitals, hospitals, medical clinics and others.
• On the basis of distribution channel, the anca vasculitis treatment market is segmented into retail store, pharmacy and e-commerce.

Global Anca Vasculitis Treatment Market Country Level Analysis

Global anca vasculitis treatment market is analysed and market size information is provided by country, type, diagnosis, treatment type, route of administration, end user and distribution channel as referenced above.

The countries covered in the anca vasculitis treatment market report are the U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.

On geographical estimation, North America accounts for the largest market share because of increasing prevalence of patients with vasculitis disease, increase healthcare expenditure and rapid awareness among population. Europe is considered as the second largest market share due to increase in advancement in healthcare sector. Asia-Pacific also holds the market share due to increase in geriatric population and government initiatives for the R&D.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

The anca vasculitis treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to anca vasculitis treatment market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the anca vasculitis treatment market in the growth period.

Cenário competitivo e análise global da quota de mercado do tratamento da vasculite Anca

O cenário competitivo do mercado de tratamento da vasculite anca fornece detalhes por concorrente. Os detalhes incluídos são a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, investimento em investigação e desenvolvimento, novas iniciativas de mercado, presença global, localizações e instalações de produção, pontos fortes e fracos da empresa, lançamento de produtos , pipelines de ensaios clínicos, aprovações de produtos, patentes, largura e amplitude do produto, domínio da aplicação, curva de segurança da tecnologia. Os dados acima fornecidos estão apenas relacionados com o foco das empresas relacionado com o mercado global de tratamento da vasculite anca.

Os principais players abrangidos no relatório global do mercado de tratamento da vasculite anca são a Novartis AG, GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd, RNL BIO Co., Ltd., Human Genome Sciences, Inc, Johnson & Johnson Services, Inc. , Genentech , Inc., AstraZeneca, Baxter International, Bristol Myers Squibb Company, Celgene Corporation, ChemoCentryx, Daiichi Sankyo, Eli Lilly & Company, Pfizer, Inc., entre outros players nacionais e globais. Os dados de quota de mercado estão disponíveis para a global, América do Norte, Europa, Ásia-Pacífico (APAC), Médio Oriente e África (MEA) e América do Sul separadamente. Os analistas DBMR compreendem os pontos fortes competitivos e fornecem análises competitivas para cada concorrente em separado.

SKU-60057